Autolus Therapeutics to Report Third Quarter 2026 Financial Results on November 10, 2026
Autolus Therapeutics plc has scheduled the release of its third quarter 2026 financial results and a corresponding conference call for November 10, 2026.
Stocks · News reference
8-K filing — Autolus Therapeutics plc (AUTL)
Filed: 2026-08-11 AccNo: 0001730463-26-000119 Size: 4 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Autolus Therapeutics Published Abstract Filed TO American College Of Rheumatology Convergence 2026
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced the online
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand
The CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Set for Strong Growth Through 2036, Driven by Next-Generation Innovation and Expanding Patient Access
The CAR-T cell therapy market for acute lymphoblastic leukemia (ALL) is projected to grow at a 6.8% CAGR from 2026 to 2036, reaching from $300 million in 2025. The market is driven by approved therapies like KYMRIAH, TECARTUS, and AUCATZYL, with emerging innovations including allogeneic platforms and CD7-targeting therapies. Key challenges include relapse rates, manufacturing complexity, and toxicity management, while opportunities exist in earlier treatment lines and off-the-shelf platforms.